Clinical Trials
27 trialsA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
eVOLVE-RCC02
AstraZeneca
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
CANIQOL
Centre Francois Baclesse
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
CABOLD
Gustave Roussy, Cancer Campus, Grand Paris
CheckMate 7C9
Bristol-Myers Squibb
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Cyto-KIK
Columbia University
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
CheckMate 914
Bristol-Myers Squibb
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das ClÃnicas de Ribeirão Preto
MK-3795-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Aravive, Inc.
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
CheckMate 76U
Bristol-Myers Squibb
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
MedImmune LLC
RADVAX
University of Texas Southwestern Medical Center
Study of Nivolumab for Advanced Cancers in India
Bristol-Myers Squibb
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
MDX1106-01
Bristol-Myers Squibb